171 related articles for article (PubMed ID: 20574049)
1. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.
Hertlein E; Triantafillou G; Sass EJ; Hessler JD; Zhang X; Jarjoura D; Lucas DM; Muthusamy N; Goldenberg DM; Lee RJ; Byrd JC
Blood; 2010 Oct; 116(14):2554-8. PubMed ID: 20574049
[TBL] [Abstract][Full Text] [Related]
2. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
3. Milatuzumab - a promising new immunotherapeutic agent.
Berkova Z; Tao RH; Samaniego F
Expert Opin Investig Drugs; 2010 Jan; 19(1):141-9. PubMed ID: 19968579
[TBL] [Abstract][Full Text] [Related]
4. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
Haran M; Mirkin V; Braester A; Harpaz N; Shevetz O; Shtreiter M; Greenberg S; Mordich O; Amram O; Binsky-Ehrenreich I; Marom A; Shachar I; Herishanu Y; Ruchlemer R; Berrebi A; Valinsky L; Shtalrid M; Shvidel L
Br J Haematol; 2018 Jul; 182(1):125-128. PubMed ID: 28466956
[No Abstract] [Full Text] [Related]
6. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
7. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.
Mark T; Martin P; Leonard JP; Niesvizky R
Expert Opin Investig Drugs; 2009 Jan; 18(1):99-104. PubMed ID: 19053886
[TBL] [Abstract][Full Text] [Related]
8. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
9. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
Robak T
Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
[TBL] [Abstract][Full Text] [Related]
10. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
[TBL] [Abstract][Full Text] [Related]
11. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.
Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G
HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875
[TBL] [Abstract][Full Text] [Related]
12. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
Robak T
Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199
[TBL] [Abstract][Full Text] [Related]
13. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
15. CD84 is a survival receptor for CLL cells.
Binsky-Ehrenreich I; Marom A; Sobotta MC; Shvidel L; Berrebi A; Hazan-Halevy I; Kay S; Aloshin A; Sagi I; Goldenberg DM; Leng L; Bucala R; Herishanu Y; Haran M; Shachar I
Oncogene; 2014 Feb; 33(8):1006-16. PubMed ID: 23435417
[TBL] [Abstract][Full Text] [Related]
16. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
[TBL] [Abstract][Full Text] [Related]
18. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Wegener WA; Goldenberg DM
Br J Haematol; 2013 Nov; 163(4):478-86. PubMed ID: 24112026
[TBL] [Abstract][Full Text] [Related]
19. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
Stein R; Qu Z; Cardillo TM; Chen S; Rosario A; Horak ID; Hansen HJ; Goldenberg DM
Blood; 2004 Dec; 104(12):3705-11. PubMed ID: 15297317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]